following assessment under the abbreviated process:
hydroxycarbamide oral solution (Xromi®) is accepted for restricted use within NHSScotland
Indication under review: for the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 2 years of age.
SMC restriction: children who are too young to be able to swallow capsules / tablets and adults and adolescents who have difficulty in swallowing solid oral dosage forms.
The availability of hydroxycarbamide oral solution (Xromi®) provides a licensed alternative to unlicensed liquid preparations.
Download detailed advice718KB (PDF)
- Medicine name:
- hydroxycarbamide (Xromi)
- SMC ID:
For the prevention of vaso-occlusive complications of Sickle Cell Disease in patients over 2 years of age.
- Pharmaceutical company
- Nova Laboratories Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Date advice published
- 10 August 2020